348 related articles for article (PubMed ID: 36786912)
1. Adenosinergic Pathway in Parkinson's Disease: Recent Advances and Therapeutic Perspective.
Zhao Y; Liu X; Yang G
Mol Neurobiol; 2023 Jun; 60(6):3054-3070. PubMed ID: 36786912
[TBL] [Abstract][Full Text] [Related]
2. Adenosine heteroreceptor complexes in the basal ganglia are implicated in Parkinson's disease and its treatment.
Borroto-Escuela DO; Fuxe K
J Neural Transm (Vienna); 2019 Apr; 126(4):455-471. PubMed ID: 30637481
[TBL] [Abstract][Full Text] [Related]
3. Interaction of adenosine receptors with other receptors from therapeutic perspective in Parkinson's disease.
Morin N; Di Paolo T
Int Rev Neurobiol; 2014; 119():151-67. PubMed ID: 25175965
[TBL] [Abstract][Full Text] [Related]
4. Can adenosine A
Kanda T; Jenner P
Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1():S21-S27. PubMed ID: 33349576
[TBL] [Abstract][Full Text] [Related]
5. Why target brain adenosine receptors? A historical perspective.
Fredholm BB; Svenningsson P
Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1():S3-S6. PubMed ID: 33349578
[TBL] [Abstract][Full Text] [Related]
6. Current and experimental treatments of Parkinson disease: A guide for neuroscientists.
Oertel W; Schulz JB
J Neurochem; 2016 Oct; 139 Suppl 1():325-337. PubMed ID: 27577098
[TBL] [Abstract][Full Text] [Related]
7. l-3,4-dihydroxyphenylalanine (l-DOPA) modulates brain iron, dopaminergic neurodegeneration and motor dysfunction in iron overload and mutant alpha-synuclein mouse models of Parkinson's disease.
Billings JL; Gordon SL; Rawling T; Doble PA; Bush AI; Adlard PA; Finkelstein DI; Hare DJ
J Neurochem; 2019 Jul; 150(1):88-106. PubMed ID: 30716176
[TBL] [Abstract][Full Text] [Related]
8. Adenosine A1 receptor stimulation reduces D1 receptor-mediated GABAergic transmission from striato-nigral terminals and attenuates l-DOPA-induced dyskinesia in dopamine-denervated mice.
Mango D; Bonito-Oliva A; Ledonne A; Cappellacci L; Petrelli R; Nisticò R; Berretta N; Fisone G; Mercuri NB
Exp Neurol; 2014 Nov; 261():733-43. PubMed ID: 25173217
[TBL] [Abstract][Full Text] [Related]
9. Targeting G Protein-Coupled Receptors in the Treatment of Parkinson's Disease.
Jones-Tabah J
J Mol Biol; 2023 Jun; 435(12):167927. PubMed ID: 36563742
[TBL] [Abstract][Full Text] [Related]
10. Altered adenosine 2A and dopamine D2 receptor availability in the 6-hydroxydopamine-treated rats with and without levodopa-induced dyskinesia.
Zhou X; Doorduin J; Elsinga PH; Dierckx RAJO; de Vries EFJ; Casteels C
Neuroimage; 2017 Aug; 157():209-218. PubMed ID: 28583881
[TBL] [Abstract][Full Text] [Related]
11. Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.
Fox SH; Chuang R; Brotchie JM
Prog Brain Res; 2008; 172():479-94. PubMed ID: 18772047
[TBL] [Abstract][Full Text] [Related]
12. Adenosine receptors and dyskinesia in pathophysiology.
Tomiyama M
Int Rev Neurobiol; 2014; 119():117-26. PubMed ID: 25175963
[TBL] [Abstract][Full Text] [Related]
13. Non-dopaminergic treatments for motor control in Parkinson's disease.
Fox SH
Drugs; 2013 Sep; 73(13):1405-15. PubMed ID: 23917951
[TBL] [Abstract][Full Text] [Related]
14. Neuromodulation in Parkinson's disease targeting opioid and cannabinoid receptors, understanding the role of NLRP3 pathway: a novel therapeutic approach.
Alam MR; Singh S
Inflammopharmacology; 2023 Aug; 31(4):1605-1627. PubMed ID: 37318694
[TBL] [Abstract][Full Text] [Related]
15. Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.
Urs NM; Bido S; Peterson SM; Daigle TL; Bass CE; Gainetdinov RR; Bezard E; Caron MG
Proc Natl Acad Sci U S A; 2015 May; 112(19):E2517-26. PubMed ID: 25918399
[TBL] [Abstract][Full Text] [Related]
16. Levodopa Therapy for Parkinson's Disease: History, Current Status and Perspectives.
Bogetofte H; Alamyar A; Blaabjerg M; Meyer M
CNS Neurol Disord Drug Targets; 2020; 19(8):572-583. PubMed ID: 32703142
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.
Andersen AD; Blaabjerg M; Binzer M; Kamal A; Thagesen H; Kjaer TW; Stenager E; Gramsbergen JBP
J Neurochem; 2017 May; 141(4):614-625. PubMed ID: 28244186
[TBL] [Abstract][Full Text] [Related]
18. The adenosine A(2A) receptor as an attractive target for Parkinson's disease treatment.
Chen JF
Drug News Perspect; 2003 Nov; 16(9):597-604. PubMed ID: 14702141
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Parkinson's disease: levodopa as the first choice.
Katzenschlager R; Lees AJ
J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
[TBL] [Abstract][Full Text] [Related]
20. The potential role of glucose metabolism, lipid metabolism, and amino acid metabolism in the treatment of Parkinson's disease.
Li H; Zeng F; Huang C; Pu Q; Thomas ER; Chen Y; Li X
CNS Neurosci Ther; 2024 Feb; 30(2):e14411. PubMed ID: 37577934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
